对阿尔茨海默氏病中心血管风险因素的元元分析
Olalla Saiz-Vazquez1, Silvia Ubillos-Landa1, Alicia Puente-Martínez2
1Universidad de Burgos, Health Sciences Department, Paseo Comendadores s/n, Burgos 09001, Spain.
eNeurologicalSci
|October 23, 2025
概括
诸如高胆固醇和血压等心血管风险因素与阿尔茨海默病 (AD) 的风险增加有关. 脑卒中也显著增加了AD风险,突出了预防这些疾病的管理的重要性.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 流行病学 流行病学
背景情况:
- 阿尔茨海默病 (AD) 是老年人痴呆的主要原因.
- 确定AD的心血管风险因素对于初级预防策略至关重要.
- 了解这些联系可能有助于减少AD的整体发病率.
研究的目的:
- 进行三项研究的元分析.
- 评估胆固醇,血压和中风对阿尔茨海默病诊断的影响.
主要方法:
- 文献搜索仅限于过去三年的元分析.
- 包括关注胆固醇,血压,中风和AD的研究.
- 遵守PRISMA系统审查指南.
主要成果:
- 胆固醇升高,特别是LDL-C,显著影响AD的发展.
- 高静脉血压 (SBP) 与阿尔茨海默病的风险增加有关.
- 缺血性中风,出血性中风和微型心脏病发作都与AD风险有显著的关联.
结论:
- 心血管疾病的风险因素明显增加患阿尔茨海默病的风险.
- 主持人分析证实了调查结果的可靠性.
- 未来的研究应该探索其他因素,如糖尿病,以进一步阐明这些关系.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Coronary Artery Disease I: Introduction
876
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
876
Dementia
515
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
515
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
458
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
458


